Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: Previous studies have shown the role of Sal-like protein 4 (SALL4) as a biomarker in hepatocellular carcinoma (HCC), and some studies have shown the relationship between SALL4 and prognosis. Given the debates in study groups differences in terms of etiologic causes between Western and Asian HCC and detection methods, we attempted to verify the features of SALL4 immunoreactivity and its clinical correlation in Korean HCC patients.
Methods: Immunohistochemical staining of SALL4 of tissue microarrays (TMAs) consisting of 213 surgically resected HCC patients’ tissue were scored in a semiquantitative scoring system with immunoreactive score and the results analyzed with clinical outcome, in addition to general demographics and clinical characteristics.
Results: SALL4 immunoreactivity was expressed in 50 cases. Relevance between SALL4 and α-FP correlated significantly (P= 0.002). Also, the SALL4-positive patients had considerably higher tumor grade (P < 0.001). The survival analysis showed negative correlation with SALL4 immunoreactivity in all HCC patient groups, but SALL4 immunoreactivity in T3 and T4 HCC correlated with poor prognosis.
Conclusion: Here, we found that positive immunostaining of SALL4 is correlated with poor patient survival outcome in large and undifferentiated Korean HCC. SALL4 expression showed close relationship with clinical outcomes of HCCs in Korean patients.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• REFERENCES

참고문헌 (Reference)

1 Han SX., "Serum SALL4 is a novel prognosis biomarker with tumor re cur rence and poor survival of patients in hepatocellular carcinoma" 2014 : 262385-, 2014

2 Oikawa T., "Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells" 136 : 1000-1011, 2009

3 Oikawa T., "Sal-like protein 4(SALL4), a stem cell biomarker in liver cancers" 57 : 146983-, 2013

4 Ma Y., "SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia(AML)and indu ces AML in transgenic mice" 108 : 2726-2735, 2006

5 Kobayashi D., "SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer" 38 : 933-939, 2011

6 Cao D., "SALL4 is a novel diagnostic marker for testicular germ cell tumors" 33 : 1065-1077, 2009

7 Liu TC., "SALL4 immunoreactivity predicts prognosis in Western hepatocellular car cinoma patients but is a rare event : a study of 236 cases" 38 : 966-972, 2014

8 Fujimoto M., "SALL4 immunohistochemistry in non-small-cell lung carcinomas" 64 : 309-311, 2014

9 Yong KJ., "Oncofetal gene SALL4 in aggressive hepatocellular carcinoma" 368 : 2266-2276, 2013

10 Llovet JM., "Molecular targeted therapies in hepatocellular carcinoma" 48 : 1312-1327, 2008

11 Bruix J., "Management of hepatocellular carcinoma : an update" 53 : 1020-1022, 2011

12 Parkin DM., "Global cancer statistics, 2002" 55 : 74-108, 2005

13 Wurmbach E., "Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma" 45 : 938-947, 2007

14 Ferlay J., "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008" 127 : 2893-2917, 2010

15 Rao S1., "Differential roles of Sall4 isoforms in embryonic stem cell pluripotency" 30 : 536480-, 2010

16 Villanueva A., "Com bining clinical, pathology, and gene ex pression data to predict recur rence of hepatocellular carcinoma" 140 : 1501.e2-1512.e2, 2011

17 Yang J., "A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells" 5 : e10766-, 2010

18 Llovet JM., "A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis" 131 : 1758-1767, 2006